A practical plan for refill delays and coverage gaps
David L. Carpenter, BSN, RN | Health Content Works
Evidence checked: October 26, 2026.
An empty prescription box can leave you trying to solve several problems at once. The pharmacy may be waiting for stock, your insurer may need more information, or the next fill may cost more than you can afford. Start by finding out exactly what is blocking the prescription and telling your prescriber how much medication you have left.
This guide focuses on the days around a treatment interruption. It covers practical questions to ask and the different missed-dose instructions for Wegovy and Zepbound. It does not provide a personal restart dose or replace the instructions for your prescription. Other GLP-1 products, including Ozempic and Mounjaro, need their own guidance.
Find out what is actually holding up the refill
Ask the pharmacy to describe the problem in plain language. “It is not ready” could mean the prescription has no refills, the strength is unavailable, the insurer considers the refill too early, or prior authorization is incomplete. Each problem has a different person who can resolve it.
Write down the next action and who owns it. If the prescriber needs to send information, ask what information is missing. If stock is the issue, ask whether the pharmacy has an estimated arrival date or can check another location. If the price changed, ask whether the claim was processed through your current insurance and what the pharmacy can tell you about the rejection.
These questions do not guarantee a fill. They make the next phone call more useful. Instead of telling the clinic “the pharmacy will not fill it,” you can explain the precise obstacle and give the pharmacy’s contact details.
A national shortage and a local supply problem are also different. FDA has acknowledged that limited local disruptions can persist after a national shortage is resolved. A pharmacy being out of your strength does not establish a new nationwide shortage or automatically justify a compounded substitute. [1]
Give the prescriber dates and details
Contact the office before your supply runs out when possible. Ask what lead time it needs for renewals and authorizations; there is no single refill schedule that fits every plan or pharmacy. Set a reminder based on the answer, rather than waiting for your last scheduled dose.
Send a short message with the following information:
- The exact product, strength, and formulation you use.
- The date of your last dose and the number of doses remaining.
- The next scheduled dose date and the pharmacy’s stated problem.
- Any recent side effects or difficulty eating or drinking.
- Whether another clinician has changed your medicines or medical care.
For example: “My next Zepbound dose is due Friday. I took my last dose last Friday and have none left. The pharmacy says my prior authorization expired. Please tell me who is handling the renewal and what to do if I cannot obtain the next dose.”
Keep the reply in a place you can find. A written plan should identify the intended product, when to contact the office again, and who will advise you if the delay becomes longer. If you use treatment alongside diabetes medicines, specifically ask whether your glucose monitoring or other treatment needs review during the interruption. Do not independently change insulin or other prescriptions.
A missed dose has product-specific instructions
The following is a summary of current U.S. prescribing information, not a direction to use a recalled, damaged, expired, or otherwise unsuitable supply. Ask a pharmacist about uncertain timing, especially if you are exactly at a cutoff.
Wegovy injection: for one missed dose, the label says to take it as soon as possible if the next scheduled dose is more than 48 hours away. If the next dose is less than 48 hours away, skip it and return to the regular day. After two or more consecutive missed doses, the prescribing information directs restarting dose escalation at a lower dose to reduce gastrointestinal reactions; have your prescriber specify the regimen. [2]
Wegovy tablets: skip a missed dose and take the next dose the following day. Do not apply the weekly injection rule to tablets. [2]
Zepbound: take a missed dose within 96 hours. After that window, skip it and resume on the usual day. Keep at least 72 hours between doses. Its missed-dose section does not supply a universal restart schedule for a prolonged interruption; ask your prescriber for one. [3]
Do not use an internet dose-conversion chart to change brands or formulations. Having an appointment scheduled does not make an improvised dose safe in the meantime.
Make the restart plan before the medicine arrives
A delivery notification tells you the package is coming. It does not answer whether the old regimen is still appropriate after a longer gap. Ask the prescriber to review the time off treatment, prior tolerability, and any changes in your health before you resume.
Get clear answers to these questions: What will I take? On what date? Will there be a new dose-escalation schedule? When should I contact the office about side effects? If a new prescription is needed, has it been sent to the pharmacy that will actually fill it?
If the presentation changes from a pen to a vial or another device, request training for that presentation. Zepbound’s labeling specifically calls for appropriate training when the presentation changes. [3] Even a familiar brand name is not a reason to assume that every package works the same way.
Storage also belongs in that conversation. FDA recommends not using injectable GLP-1 medicine delivered warm or inadequately refrigerated because its quality may be affected. The agency has received complaints about compounded GLP-1 shipments arriving warm or with inadequate ice packs. [4] Do not use that supply or judge its usability by how the liquid looks. Contact the dispensing pharmacy about a replacement. Also report any freezing, time spent outside, or uncertainty about when a container was opened, and ask for product-specific instructions before using a questionable supply.
Keep the daily routine workable during the gap
While the medication issue is being sorted out, choose a few manageable routines you can continue. Put familiar meals on the shopping list. Plan food for a long shift. Keep a place to record questions for the next appointment. These are practical ways to reduce the number of decisions you face; they are not a proven substitute for medication or a promise to prevent weight regain.
If hunger, eating patterns, or weight change, describe what you notice to your care team. Avoid treating each change as evidence that you have failed. The useful question is what support you need while access is uncertain. If tracking weight increases distress, ask the clinician how to monitor progress in a way that works for you.
The STEP 1 extension followed a selected subset of participants for about a year after study treatment and structured lifestyle support ended. People who had taken semaglutide regained a substantial share of the weight they had lost, on average. The extension was exploratory, manufacturer-funded, and studied a much longer withdrawal period than a brief refill delay. It cannot predict what will happen to you after one missed dose or a short gap. [5] For the longer-term evidence, see what happens when treatment stops.
Bring up symptoms separately from weight concerns. Persistent vomiting, inability to keep fluids down, or severe abdominal pain should prompt medical advice rather than waiting for a routine refill reply. Both products warn about serious gastrointestinal problems and dehydration-related kidney injury; their Medication Guides direct stopping treatment and contacting a clinician immediately for severe abdominal pain that does not go away. Seek emergency care for severe or life-threatening symptoms. [2,3]
Avoid turning an access problem into a dosing problem
Tell the office directly if cost is the barrier and what monthly amount you can realistically manage. Ask about a sustainable treatment option and a follow-up plan. This discussion can happen alongside insurance work; you do not have to conceal the financial problem until every appeal is complete.
Do not assume that a friend’s spare supply, a seller in a social group, or a product labeled for research is an appropriate replacement. FDA recommends a prescription filled through a state-licensed pharmacy and warns about unapproved GLP-1 products and unreliable sellers. A quick offer is not a substitute for knowing who prescribed, prepared, and dispensed the medicine. [4]
If a compounded product is being considered for a legitimate medical need, ask the prescriber and pharmacist to explain it. A new vial can have a different concentration. The same syringe marking may therefore deliver a different amount of medicine. FDA has documented compounded semaglutide dosing errors involving confusion between milligrams, milliliters, and units, sometimes requiring hospitalization. Have the pharmacist demonstrate the exact dose rather than calculating a substitute yourself. [6]
Leave the next conversation with a usable plan
Before ending the call, repeat back the next step: who is handling the prescription, when you should expect an update, and whom to contact if that deadline passes. Confirm what to do about the next scheduled dose and whether a longer delay changes the plan.
Keep the pharmacy, prescriber, and insurer messages together so you do not have to reconstruct the story each time. Our insurance-coverage article addresses coverage and cost routes in more detail; this plan is about keeping communication and medication instructions clear while the refill is unresolved. You should not have to guess your way through the gap.
This article provides general education and does not replace advice from your prescriber or pharmacist.
Sources and evidence notes
[1] FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. April 1, 2026 update and earlier shortage discussion. Open source
[2] Novo Nordisk. Wegovy (semaglutide) injection and tablets, U.S. Prescribing Information and Medication Guide, revised June 2026. Sections 2.4, 5.2, 5.5 and 5.6. Open source
[3] Eli Lilly. Zepbound U.S. Prescribing Information, revised August 2026. Sections 2.3, 2.4, 5.2, 5.3 and 5.5; accompanying patient labeling. Open source | Medication Guide
[4] FDA. Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Shipping, pharmacy and patient recommendations. Accessed October 26, 2026. Open source
[5] Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide The STEP 1 trial extension. Diabetes Obesity and Metabolism. 2022;24:1553–1564. DOI 10.1111/dom.14725. PMID 35441470. Open source
[6] FDA. Dosing errors associated with compounded injectable semaglutide products. Open source
Leave a Reply